Canaccord lowered the firm’s price target on Inari Medical to $68 from $84 and keeps a Buy rating on the shares. The firm said they reported solid Q3 results but their recent acquisition has pushed out the timeline to sustainable profitability.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NARI:
- Inari Medical to Present at Upcoming Investor Conferences
- Inari Medical Inari raises FY23 revenue view to $490M-$493M, consensus $487.9M
- Inari Medical to acquire privately held LimFlow for $250M in cash
- Inari Medical to acquire LimFlow in up to $415M deal
- Inari Medical reports Q3 EPS 5c, consensus 0c